Veralox Therapeutics to Acquire Nudge Therapeutics, Expanding its Portfolio
Shots:
- Veralox has signed an exclusive agreement to acquire Nudge Therapeutics & its preclinical cyclic AMP-GMP (cGAS) inhibitors. The financial terms were undisclosed
- As per the terms, Veralox will resume the development of acquired candidates & initiate acquisition upon achievement of downstream milestones
- In addition, Veralox is developing VLX-1005 (12-LOX inhibitor) for thrombosis linked to heparin-induced thrombocytopenia (HIT) that showed favourable safety & tolerability in 2 P-I studies involving 96 healthy subjects. Its P-II (VLX-1005-003) trial is now enrolling patients at 14 sites & expected to achieve clinical PoC in 2025
Ref: Prnewswire | Image: Veralox Therapeutics
Related News:- Transcarent to Acquire Accolade for ~$621M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
